publication date: May. 12, 2017
How one bad sentence in the Cures Act blocked FDA’s cancer center from receiving $75 million
By Matthew Bin Han Ong
The FDA Oncology Center of Excellence occupied a special place in the Obama White House moonshot program.
Amid the moonshot’s big goals, the FDA center was concrete, manageable, and modestly priced, a reorganization that promised to revolutionize the agency’s handling of everything cancer.
How is the place faring today?
Not well, by anyone’s standards.
The long-awaited center that was designed to focus the entire FDA oncology portfolio in one administrative unit staffed by cancer experts is caught up in a classic Catch-22 impasse. The money for the center exists. It has even been appropriated. But because of what looks like a language snafu by Congressional authorizing committees, the money is, for the foreseeable future, stuck at NIH.
Congress had the capacity to fix the problem in the recently passed FY2017 spending bill, but, alas, didn’t. In principle, an interagency agreement can be used to pry the money out of NIH, but that path comes with unexpected twists.
When Congress passed the 21st Century Cures Act in December 2016, authorizers set aside $1.8 billion for cancer research via NIH and NCI over seven years. Of that … Continue reading How one bad sentence in the Cures Act blocked FDA’s cancer center from receiving $75 million
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.